Shanghai RAAS(SZ:002252) Zheng Quan Zhi Xing·2025-09-04 11:14Core Viewpoint - The management team of Shanghai Laishi Blood Products Co., Ltd. plans to increase their shareholding in the company, demonstrating confidence in the company's strategic development and long-term investment value, with a total planned investment of no less than RMB 6 million within six months [2][3]. Group 1: Shareholding Increase Plan - The increase in shareholding will be executed through centralized bidding, funded by self-raised capital [2][3]. - The management team members involved in the shareholding increase include Jun Xu, Shen Jihui, Lu Hui, Liu Zheng, Song Zhengmin, Chen Leqi, and Huang Qinbing, with their current shareholdings detailed in a table [2][3]. - The total number of shares held by the management team members, excluding those from the first employee stock ownership plan, is specified [2][3]. Group 2: Employee Stock Ownership Plan - As of the announcement date, the management team members hold remaining shares corresponding to the first employee stock ownership plan, which will only be realized upon meeting specific unlocking conditions [3]. - The management team has previously sold shares obtained from the first employee stock ownership plan after the lock-up period [3]. Group 3: Implementation Conditions - The shareholding increase plan will be executed based on a reasonable assessment of the company's stock value, and the implementation may be postponed if the stock is suspended or if market conditions change [4]. - The management team commits to not reducing their shareholdings during the implementation period and will adhere to relevant laws and regulations [4].